Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 nov. 2020 16h06 HE | Source: Eyenovia, Inc.

Eyenovia Reports Third Quarter 2020 Financial Results

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
05 nov. 2020 08h00 HE | Source: Eyenovia, Inc.

Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
13 oct. 2020 07h00 HE | Source: Eyenovia, Inc.

Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million

Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results Call scheduled for today, Tuesday, October 13 at 4:30pm ET ...
09 sept. 2020 08h30 HE | Source: Eyenovia, Inc.

Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
24 août 2020 08h30 HE | Source: Eyenovia, Inc.

Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering

NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
21 août 2020 16h05 HE | Source: Eyenovia, Inc.

Eyenovia, Inc. Announces Closing of Offering of Common Stock

NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
19 août 2020 09h10 HE | Source: Eyenovia, Inc.

Eyenovia, Inc. Prices Public Offering of Common Stock

NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
18 août 2020 16h03 HE | Source: Eyenovia, Inc.

Eyenovia, Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
12 août 2020 16h05 HE | Source: Eyenovia, Inc.

Eyenovia Reports Second Quarter 2020 Financial Results

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
11 août 2020 08h00 HE | Source: Eyenovia, Inc.

Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea

Eyenovia Eligible to Receive up to a Total of $45.75 million in Upfront Payments and Development and Commercialization Milestones and Development Costs Arctic Vision to Lead Expansion of Novel...

Page précédente